Sun Pharma-Ranbaxy deal may come under Sebi lens

The capital markets regulator, Securities and Exchange Board of India, is likely to begin a preliminary inquiry into the $4-billion merger deal between pharma giants Sun Pharmaceutical and Ranbaxy......

Indian bourses' nod for Sun Pharma-Ranbaxy deal

The $4-billion merger of Ranbaxy Labs with Sun Pharmaceutical has got clearance from the two leading stock exchanges – Bombay Stock Exchange and National Stock Exchange. The 'no-objection'......

Maintain status-quo on Sun Pharma-Ranbaxy merger: HC to bourses

  In a setback to Sun Pharma-Ranbaxy merger process, Andhra Pradesh High Court has issued orders to Bombay Stock Exchange and National Stock Exchange to maintain interim status quo on the......

Meet the man behind the Sun Pharma-Ranbaxy deal

Israel Makov, the 75-year-old chairman of Sun Pharmaceutical, pushed through the deal to acquire Ranbaxy at a six-hour board meeting on Sunday. Makov’s contribution was not limited to......